Evidence map›Paper›PMID 34771479›Full record

ArticleCancers2021

Standardization and Validation of Brachytherapy Seeds' Modelling Using GATE and GGEMS Monte Carlo Toolkits.

Konstantinos P Chatzipapas, Dimitris Plachouris, Panagiotis Papadimitroulas, Konstantinos A Mountris, Julien Bert, Dimitris Visvikis, Dimitris Mihailidis, George C Kagadis

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. PersonalisedFrontiers in physiology · 2024
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Konstantinos P Chatzipapas3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, 26504 Rion, Greece.ORCID 0000-0003-4006-9304
Dimitris Plachouris3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, 26504 Rion, Greece.ORCID 0000-0003-2261-0865
Panagiotis PapadimitroulasBioemission Technology Solutions (BIOEMTECH), 15343 Athens, Greece.ORCID 0000-0002-5981-6149
Konstantinos A MountrisAragon Institute of Engineering Research, IIS Aragon, University of Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0003-2946-3044
Julien BertLaTIM, INSERM, UMR1101, Camille Desmoulins Av. 22, 29200 Brest, France.ORCID 0000-0002-2756-942X
Dimitris VisvikisLaTIM, INSERM, UMR1101, Camille Desmoulins Av. 22, 29200 Brest, France.
Dimitris MihailidisRadiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
George C Kagadis3DMI Research Group, Department of Medical Physics, School of Medicine, University of Patras, 26504 Rion, Greece.ORCID 0000-0002-6983-2863
University of Patras · GRInserm · FRUniversidad de Zaragoza · ESUniversity of Pennsylvania · US

Funding

Horizon 2020 872735
6 · The paper itself

Abstract

This study aims to validate GATE and GGEMS simulation toolkits for brachytherapy applications and to provide accurate models for six commercial brachytherapy seeds, which will be freely available for research purposes. The AAPM TG-43 guidelines were used for the validation of two Low Dose Rate (LDR), three High Dose Rate (HDR), and one Pulsed Dose Rate (PDR) brachytherapy seeds. Each seed was represented as a 3D model and then simulated in GATE to produce one single Phase-Space (PHSP) per seed. To test the validity of the simulations' outcome, referenced data (provided by the TG-43) was compared with GATE results. Next, validation of the GGEMS toolkit was achieved by comparing its outcome with the GATE MC simulations, incorporating clinical data. The simulation outcomes on the radial dose function (RDF), anisotropy function (AF), and dose rate constant (DRC) for the six commercial seeds were compared with TG-43 values. The statistical uncertainty was limited to 1% for RDF, to 6% (maximum) for AF, and to 2.7% (maximum) for the DRC. GGEMS provided a good agreement with GATE when compared in different situations: (a) Homogeneous water sphere, (b) heterogeneous CT phantom, and (c) a realistic clinical case. In addition, GGEMS has the advantage of very fast simulations. For the clinical case, where TG-186 guidelines were considered, GATE required 1 h for the simulation while GGEMS needed 162 s to reach the same statistical uncertainty. This study produced accurate models and simulations of their emitted spectrum of commonly used commercial brachytherapy seeds which are freely available to the scientific community. Furthermore, GGEMS was validated as an MC GPU based tool for brachytherapy. More research is deemed necessary for the expansion of brachytherapy seed modeling.

Indexed as

brachytherapyGATEGGEMSMonte Carlo simulationsTG-186TG-43

Identifiers

PMID34771479
PMCPMC8582469
OpenAlexW3210754162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.